BOSTON--(BUSINESS WIRE)--Feb. 24, 2015--
to Tweet this News) Flex Pharma, Inc. (NASDAQ: FLKS), a
biotechnology company that is developing innovative and proprietary
treatments for nocturnal leg cramps and spasms associated with severe
neuromuscular conditions, today announced that Nobel Laureate and
Scientific Co-Founder, Rod MacKinnon, M.D., has joined its Board of
Directors. In addition, Scientific Co-Founder, Bruce Bean, Ph.D., will
join the Board as an observer based upon his significant contributions
and ongoing involvement with the Company’s development efforts.
Dr. MacKinnon was awarded the Nobel Prize in Chemistry in 2003 for his
work determining the structure of ion channels and showing the mechanism
by which they select for particular ions (Doyle, et al., The Structure
of the Potassium Channel: Molecular Basis of K+ Conduction and
Selectivity, April 1998, Science). His work serves as the
foundation of Flex Pharma’s approach to preventing muscle cramping. Dr.
MacKinnon is Investigator at Howard Hughes Medical Institute and the
John D. Rockefeller Jr. Professor, Laboratory of Molecular Neurobiology
and Biophysics at the Rockefeller University, and a member of the
National Academy of Sciences.
Dr. Bean, Flex Pharma Scientific Co-Founder and Co-Chair of the
Company’s Scientific Advisory Board, is a member of the National Academy
of Sciences and the Robert Winthrop Professor of Neurobiology at Harvard
Medical School, where he oversees a leading research laboratory studying
the biophysics of sodium, calcium and potassium ion signaling in
relation to pain processing.
“As a Scientific Co-Founder, I am thrilled to join the Board of Flex
Pharma and look forward to further advancing the translation of our
novel insights into treatments that can help the many individuals
suffering from cramps and spasms associated with a broad range of
neuromuscular disorders,” commented Rod MacKinnon, M.D., Nobel Laureate
and Flex Pharma Co-Founder and Co-Chair of the Company’s Scientific
“The Board of Flex Pharma is privileged to work with world class
physicians and scientists, such as Dr. MacKinnon and Dr. Bean, whose
amazing scientific insights appear to have solved a long-standing
medical mystery, unraveling the cause of muscle cramping, thereby
providing a potential solution for athletes and patients who suffer from
muscle cramps,” said Flex Pharma Board member and investor, John
Sculley, former CEO of Pepsi and Apple.
About Flex Pharma
Flex Pharma, Inc. is a biotechnology company that is developing
innovative and proprietary treatments for nocturnal leg cramps and
spasms associated with severe neuromuscular conditions. In three
randomized, blinded, placebo-controlled, cross-over studies, Flex
Pharma's proprietary treatment has shown a statistically significant
reduction in the intensity of muscle cramps in healthy normal volunteers.
Flex Pharma was founded by National Academy of Science members Rod
MacKinnon, M.D. (2003 Nobel Laureate), and Bruce Bean, Ph.D., recognized
leaders in the fields of ion channels and neurobiology, along with
Chairman and Chief Executive Officer Christoph Westphal, M.D., Ph.D.
Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements for purposes of
the safe harbor provisions of the Private Securities Litigation Reform
Act of 1995. We may, in some cases, use terms such as “predicts,”
“believes,” “potential,” “proposed,” “continue,” “estimates,”
“anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,”
“will,” “should” or other words that convey uncertainty of future events
or outcomes to identify these forward-looking statements.
Forward-looking statements include statements regarding our intentions,
beliefs, projections, outlook, analyses or current expectations
concerning, among other things: the success and timing of ongoing and
anticipated clinical studies for our current product candidates; our
expectations regarding the effectiveness and safety of our product
candidates; and the timing of and our expectations for the launch of our
consumer product. Various factors may cause differences between our
expectations and actual results as discussed in greater detail under the
heading “Risk Factors” in the registration statement on Form S-1
(commission file number 333-201276), which was declared effective by the
Securities and Exchange Commission (SEC) on January 28, 2015. Any
forward-looking statements that we make in this press release speak only
as of the date of this press release. We assume no obligation to update
our forward-looking statements whether as a result of new information,
future events or otherwise, after the date of this press release.
Source: Flex Pharma, Inc.
Flex Pharma, Inc.
Elizabeth Woo, 617-874-1829
Relations & Corporate Communications